Erika P. Hamilton, MD, discusses the data leading up to the Next MONARCH 1 study of abemaciclib plus tamoxifen or abemaciclib alone with metastatic breast cancer.
Erika P. Hamilton, MD, director of the Breast Cancer and Gynecologic Cancer Research Program and principal investigator at the Sarah Cannon Research Institute, discusses the data leading up to the Next MONARCH 1 study (NCT02747004) of abemaciclib (Verzenio) plus tamoxifen or abemaciclib alone with metastatic breast cancer.
According to Hamilton, there are lots of data in the first- and second-line setting around the use of CDK4/6 inhibitors such as abemaciclib, palbociclib (Ibrance), and ribociclib (Kisqali). Abemaciclib is the only CDK4/6 inhibitor that has a single-agent approval.
A similar study to Next MONARCH 1 was MONARCH 1 (NCT02102490), which evaluated abemaciclib in patients with hormonally driven breast cancer who had received at least 2 prior lines of chemotherapy. This study was very different from other studies of CDK4/6 inhibitors in the first- and second-line setting. The MONARCH 1 study showed that abemaciclib does have single-agent activity.
Next MONARCH 1 was split into 3 arms. In arm 1, patients were given abemaciclib and tamoxifen (Nolvadex). In arm 2, patients were given abemaciclib alone. In arm 3, they were given abemaciclib and a prophylactic.
Results found that while progression-free survival did not change significantly between the arms, overall survival in arm A ranged from 17 to 24 months. According to Hamilton, abemaciclib could be a good option for patients who do not respond to endocrine therapy.
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Postoperative Radiation Improves HRQOL Over Endocrine Therapy in Breast Cancer
December 13th 2024In the phase 3 EUROPA trial, exclusive postoperative radiation therapy led to better health-related quality of life and fewer treatment-related adverse events in older patients with stage I luminal-like breast cancer at 24 months.
Read More